Journal of Peking University(Health Sciences) >
Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma
Received date: 2022-03-19
Online published: 2022-08-11
Supported by
the National Natural Science Foundation of China(81872086);the Peking University People's Hospital Scientific Research Developments Funds(RDY2018-18)
Objective: To investigate the effects of MetS on the prognosis of patients with clear cell renal cell carcinoma (ccRCC). Methods: Clinical and pathological data and the laboratory test of ccRCC 342 patients with diverticular stones who underwent ccRCC who underwent radical or partial nephrectomy were retrospectively collected and analyzed.The patients were divided into MetS group and non-MetS group, and the subgroups were defined according to the tumor size. The overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) of the two groups were analyzed by univariate Cox analysis, and the subgroup analyses were also performed. Kaplan-Meier survival curve and survival analysis for OS, CSS, and PFS of the two groups and the subgroups were conducted. Results: Univariate Cox analysis showed that MetS was a protective factor of postoperative OS [hazard ratio (HR)=0.551, 95%CI: 0.321-0.949, P=0.031], CSS (HR=0.460, 95%CI: 0.234-0.905, P=0.025), and PFS (HR 0.585, 95%CI: 0.343-0.998, P=0.049) in the patients with ccRCC. In the subgroup with tumor size≤4 cm, MetS was not associated with postoperative OS (HR=0.857, 95%CI: 0.389-1.890, P=0.702), CSS (HR=1.129, 95%CI: 0.364-3.502, P=0.833), and PFS (HR=1.554, 95%CI: 0.625-3.864, P=0.343). In the subgroup with tumor size>4 cm, Mets was a protective factor of postoperative OS (HR=0.377, 95%CI: 0.175-0.812, P=0.013), CSS (HR=0.280, 95%CI: 0.113-0.690, P=0.006), and PFS (HR=0.332, 95%CI: 0.157-0.659, P=0.002); Obesity was a protective factor of postoperative CSS (HR=0.464, 95%CI: 0.219-0.981, P=0.044), and PFS (HR=0.445, 95%CI: 0.238-0.833, P=0.011). Kaplan-Meier survival analysis showed that the long-term survival of patients with MetS was better than those without MetS in OS (P=0.029), CSS (P=0.021), and PFS (P=0.046); for the subgroup with tumor size≤4 cm, there was no significant difference in postoperative OS (P=0.702), CSS (P=0.833), and PFS (P=0.339) between patients with and without MetS; For the subgroup with tumor size>4 cm, the OS (P=0.010), CSS (P=0.003), and PFS (P=0.001) of patients with MetS were better than those without MetS. Conclusion: MetS was a protective factor of postoperative OS, CSS, and PFS in the patients with ccRCC, which was more obvious in subgroup with tumor size>4 cm. And obesity, the component of MetS, was correlated with postoperative OS and CSS.
Mei-ni ZUO , Yi-qing DU , Lu-ping YU , Xiang DAI , Tao XU . Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma[J]. Journal of Peking University(Health Sciences), 2022 , 54(4) : 636 -643 . DOI: 10.19723/j.issn.1671-167X.2022.04.009
| 1 | Bray F , Ferlay J , Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68 (6): 394- 424. |
| 2 | Ozbek E , Otunctemur A , Sahin S , et al. Renal cell carcinoma is more aggressive in Turkish patients with the metabolic syndrome[J]. Asian Pac J Cancer Prev, 2013, 14 (12): 7351- 7354. |
| 3 | Chakiryan NH, Jiang DD, Gillis KA, et al. Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma[J]. JAMA Netw Open, 2021, 4(5): e2111329[2022-03-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150693/. |
| 4 | Jonasch E , Walker CL , Rathmell WK . Clear cell renal cell carcinoma ontogeny and mechanisms of lethality[J]. Nat Rev Nephrol, 2021, 17 (4): 245- 261. |
| 5 | Zhang GM , Zhu Y , Ye DW . Metabolic syndrome and renal cell carcinoma[J]. World J Surg Oncol, 2014, 12, 236. |
| 6 | Yao F , Bo Y , Zhao L , et al. Prevalence and influencing factors of metabolic syndrome among adults in China from 2015 to 2017[J]. Nutrients, 2021, 13 (12): 4475. |
| 7 | Bovolini A , Garcia J , Andrade MA , et al. Metabolic syndrome pathophysiology and predisposing factors[J]. Int J Sports Med, 2021, 42 (3): 199- 214. |
| 8 | Ewertz M , Jensen MB , Gunnarsdóttir K , et al. Effect of obesity on prognosis after early-stage breast cancer[J]. J Clin Oncol, 2011, 29 (1): 25- 31. |
| 9 | Qi J , An R , Bhatti P , et al. Anti-hypertensive medications and risk of colorectal cancer: A systematic review and meta-analysis[J]. Cancer Causes Control, 2022, 33 (6): 801- 812. |
| 10 | Yang X, Li X, Dong Y, et al. Effects of metabolic syndrome and its components on the prognosis of endometrial cancer[J]. Front Endocrinol (Lausanne), 2021, 12: 780769[2022-03-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717682/. |
| 11 | Bulut S , Aktas BK , Erkmen AE , et al. Metabolic syndrome prevalence in renal cell cancer patients[J]. Asian Pac J Cancer Prev, 2014, 15 (18): 7925- 7928. |
| 12 | Yu Y , Gong L , Ye J . The role of aberrant metabolism in cancer: Insights into the interplay between cell metabolic reprogramming, metabolic syndrome, and cancer[J]. Front Oncol, 2020, 10, 942. |
| 13 | Luzzago S , Palumbo C , Rosiello G , et al. Metabolic syndrome predicts worse perioperative outcomes in patients treated with partial nephrectomy for renal cell carcinoma[J]. Urology, 2020, 140, 91- 97. |
| 14 | Zhang Y , Wu T , Xie J , et al. Effects of metabolic syndrome on renal function after radical nephrectomy in patients with renal cell carcinoma[J]. Int Urol Nephrol, 2021, 53 (10): 2127- 2135. |
| 15 | Kriegmair MC , Mandel P , Porubsky S , et al. Metabolic syndrome negatively impacts the outcome of localized renal cell carcinoma[J]. Horm Cancer, 2017, 8 (2): 127- 134. |
| 16 | Liu Z , Wang H , Zhang L , et al. Metabolic syndrome is associated with improved cancer-specific survival in patients with localized clear cell renal cell carcinoma[J]. Transl Androl Urol, 2019, 8 (5): 507- 518. |
| 17 | Eskelinen TJ , Kotsar A , Tammela TLJ , et al. Components of metabolic syndrome and prognosis of renal cell cancer[J]. Scand J Urol, 2017, 51 (6): 435- 441. |
| 18 | Du Y , Yang W , Liu H , et al. Perirenal fat as a new independent prognostic factor in patients with surgically treated clear cell renal cell carcinoma[J]. Clin Genitourin Cancer, 2022, 20 (1): e75- e80. |
| 19 | Ford E S . Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S[J]. Diabetes Care, 2005, 28 (11): 2745- 2749. |
| 20 | Liu M , Wang J , Jiang B , et al. Increasing prevalence of metabolic syndrome in a Chinese elderly population: 2001-2010[J]. PLoS One, 2013, 8 (6): e66233. |
| 21 | Capitanio U , Bensalah K , Bex A , et al. Epidemiology of renal cell carcinoma[J]. Eur Urol, 2019, 75 (1): 74- 84. |
| 22 | Miricescu D , Balan DG , Tulin A , et al. PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review)[J]. Exp Ther Med, 2021, 21 (5): 540. |
| 23 | Silva A , Pereira SS , Monteiro MP , et al. Effect of metabolic syndrome and individual components on colon cancer characteristics and prognosis[J]. Front Oncol, 2021, 11, 631257. |
| 24 | Mallik R , Chowdhury TA . Metformin in cancer[J]. Diabetes Res Clin Pract, 2018, 143, 409- 419. |
| 25 | Parker AS , Lohse CM , Cheville JC , et al. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma[J]. Urology, 2006, 68 (4): 741- 746. |
| 26 | Wu X , Wang Q , Wang Z , et al. Association of extrarenal invasion patterns and tumor size with the differences in survival outcomes of t3a renal cell carcinoma: a proposal modified T3a stage system is needed[J]. Int J Gen Med, 2022, 15, 367- 378. |
| 27 | Dinatale RG , Xie W , Becerra MF , et al. The association between small primary tumor size and prognosis in metastatic renal cell carcinoma: Insights from two independent cohorts of patients who underwent cytoreductive nephrectomy[J]. Eur Urol Oncol, 2020, 3 (1): 47- 56. |
/
| 〈 |
|
〉 |